AI drug developer “British Silicon Intelligence”, or listed in Hong Kong. The IPO team includes CICC and Morgan Stanley
Foreign news quoted people familiar with the matter as saying that Insilico Medicine (Insilico Medicine), an AI drug developer, plans to go public in Hong Kong and has appointed CICC and Morgan Stanley to carry out related work. Inco Intelligence expects to raise about 200 million US dollars in capital.
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech
Phoenix Biotech to Take Intrinsic Medicine Public in SPAC Deal
11:39 AM EDT, 10/31/2022 (MT Newswires) -- Phoenix Biotech Acquisition (PBAX), a blank-check company, and Intrinsic Medicine said Monday they have agreed to merge in a deal that would take Intrinsic p
Press Release: Intrinsic Medicine and Phoenix -2-
Intrinsic Medicine, Inc. is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human milk oligosaccharides (HMOs), as new medicines to treat large patient populations u
Intrinsic Medicine Files to Withdraw Planned IPO
By Stephen Nakrosis Intrinsic Medicine Inc. filed a request with the U.S. Securities and Exchange Commission to withdraw its planned initial public offering. In the filing, the company said it has d
Intrinsic Medicine Withdraws IPO Filing
Intrinsic Medicine Withdraws IPO Filing
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology BridgeBio Pharma Inc (
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:IBB)
No Data